Unfortunately, due to the lack of clinical studies using selective β3-AR antagonists in humans, the role of β3-AR subtype in melanoma cancer has not been clarified so far at clinical level; nevertheless, its contribution to processes related to melanoma progression is becoming evident, as suggested by pre-clinical evidences. This evidence concerns the gene ADRB3 and melanoma.